DOES TIMING OF CYP2C19 TESTING AFFECT MAJOR ADVERSE CARDIOVASCULAR EVENT AND BLEEDING RISK IN PATIENTS INITIATED ON DUAL ANTI-PLATELET THERAPY? REAL-WORLD EXPERIENCE FROM A POPULATION GENOMIC SCREENING PROGRAM

Authors :: Muhammad Hamza Saad Shaukat
Amanda Massmann
Joel Van Heukelom
Mikayla Knouse
Patryk Stys
Abby Glanzer
Jerome Rotter
Shaopeng Gu
Kurt Christensen
Xiuqing Guo
Madison Hickingbotham
Emilie Zoltick
Eric Larson
Catherine Hajek
Marian S. Petrasko
Naveen Rajpurohit
Adam T. Stys
Tomasz P. Stys
Source :: Journal of the American College of Cardiology. 81:1219
Publication Year :: 2023
Publisher :: Elsevier BV, 2023.

Tools